Skip to main content

Supervillin Antibody (3-2#)

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-41691

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP3-41691

Key Product Details

Species Reactivity

Human

Applications

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2a Kappa Clone # 3-2#

Concentration

1 mg/ml

Product Specifications

Immunogen

Immunized with recombinant Human Supervillin (Uniprot#: O95425; Gln1617-Phe1788 (Uniprot#: O95425)

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2a Kappa

Scientific Data Images for Supervillin Antibody (3-2#)

Supervillin Antibody (3-2#)

Western Blot: Supervillin Antibody (3-2#) [NBP3-41691] -

Western Blot: Supervillin Antibody (3-2#) [NBP3-41691] - Sample: Recombinant Supervillin, Human.

Applications for Supervillin Antibody (3-2#)

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

5-20ug/mL

Immunohistochemistry

5-20ug/mL

Western Blot

0.01-2ug/mL

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

0.01M PBS, pH7.4, 50% glycerol

Preservative

0.05% Proclin 300

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: Supervillin

SVIL - supervillin

Alternate Names

Archvillin, p205/p250, SVIL

Gene Symbol

SVIL

Additional Supervillin Products

Product Documents for Supervillin Antibody (3-2#)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Supervillin Antibody (3-2#)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...